Kentucky Administrative Regulations › Title 201 - GENERAL GOVERNMENT CABINET › Chapter 9 - Board of Medical Licensure › Section 201 KAR 9:270 - Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone

Current through Register Vol. 51, No. 1, July 1, 2024
RELATES TO:
				KRS
				218A.205, 311.530-311.620, 311.840-311.862,
				311.990
NECESSITY, FUNCTION, AND CONFORMITY:
				KRS
				311.565(1)(a) authorizes the
				board to promulgate administrative regulations to regulate the conduct of its
				licensees.
				KRS
				218A.205(3)(a) and (b)
				require the board to establish mandatory prescribing and dispensing standards
				related to controlled substances.
				KRS
				311.842(1)(b) requires that
				the board promulgate administrative regulations establishing professional
				standards for prescribing and administering controlled substances by physician
				assistants. This administrative regulation establishes the professional
				standards for any board licensee who prescribes, dispenses, or administers
				Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone in the
				Commonwealth of Kentucky. Nothing within this administrative regulation shall
				be interpreted to grant physician assistants authority to dispense
				Buprenorphine-Mono-Product or Buprenorphine-Combined-With-Naloxone, unless
				otherwise authorized by
				KRS
				311.842.
Section
			 1. Minimum Qualifications for Prescribing, Dispensing, or
			 Administering Buprenorphine-Mono-Product or
			 Buprenorphine-Combined-with-Naloxone. Except as provided in Section 3 of this
			 administrative regulation, a licensee shall not prescribe, dispense, or
			 administer Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone
			 unless that licensee possesses the minimum qualifications established in this
			 section.
(1) The licensee shall obtain and
			 maintain in good standing a waiver and license as issued by the Drug
			 Enforcement Administration (DEA) to prescribe Buprenorphine-Mono-Product or
			 Buprenorphine-Combined-with-Naloxone for the treatment of opioid use disorder
			 in the Commonwealth of Kentucky.
(2) The licensee shall successfully complete
			 the approved educational programs required by this subsection.
(a) The prescribing licensee shall be a
			 DEA-licensed prescriber of Buprenorphine-Mono-Product or
			 Buprenorphine-Combined-with-Naloxone and shall have obtained Buprenorphine
			 certification through completion of a Substance Abuse and Mental Health
			 Services Administration ("SAMHSA") certified course.
(b) For each three (3) year continuing
			 education cycle, each DEA-licensed prescriber of Buprenorphine-Mono-Product or
			 Buprenorphine-Combined-with-Naloxone shall complete at least twelve (12) hours
			 of continuing medical education certified in Category I specific to addiction
			 medicine as part of the required continuing medical education hours set forth
			 in
			 201 KAR
			 9:310 and
			 201
			 KAR 9:360.
(3) The licensee shall enroll in the Kentucky
			 Health Information Exchange to the extent necessary to query and pull
			 information from the Kentucky Health Information Exchange. The licensee shall
			 not report the prescribing, dispensing, or administering
			 Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone for
			 medically-supervised withdrawal or as maintenance treatment for a patient
			 diagnosed with opioid use disorder into the Kentucky Health Information
			 Exchange unless otherwise required by law.